Page last updated: 2024-08-16

tulobuterol and (9R)-9-chloro-11,17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one

tulobuterol has been researched along with (9R)-9-chloro-11,17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Horiguchi, T; Kondo, R; Miyazaki, J; Tachikawa, S; Torigoe, H	1
Abe, T; Arisaka, O; Yamada, Y; Yoshihara, S	1

Trials

2 trial(s) available for tulobuterol and (9R)-9-chloro-11,17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one

Article	Year
[Clinical evaluation of tulobuterol patch in patients with mild or moderate persistent bronchial asthma-effects of long-term treatment on airway inflammation and hypersensitivity]. Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 2004, Volume: 42, Issue:2 Topics: Administration, Cutaneous; Administration, Inhalation; Adrenergic beta-Agonists; Aged; Androstadienes; Asthma; Beclomethasone; Bronchial Hyperreactivity; Delayed-Action Preparations; Drug Therapy, Combination; Female; Fluticasone; Humans; Inflammation; Male; Middle Aged; Peak Expiratory Flow Rate; Quality of Life; Severity of Illness Index; Terbutaline; Time Factors; Treatment Outcome	2004
The use of patch formulation of tulobuterol, a long-acting beta2-adrenoreceptor agonist, in the treatment of severe pediatric asthma. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2006, Volume: 96, Issue:6 Topics: Administration, Cutaneous; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Asthma; Beclomethasone; Bronchodilator Agents; Child; Drug Therapy, Combination; Humans; Peak Expiratory Flow Rate; Terbutaline	2006

Article

Year

[Clinical evaluation of tulobuterol patch in patients with mild or moderate persistent bronchial asthma-effects of long-term treatment on airway inflammation and hypersensitivity].

Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 2004, Volume: 42, Issue:2

Topics: Administration, Cutaneous; Administration, Inhalation; Adrenergic beta-Agonists; Aged; Androstadienes; Asthma; Beclomethasone; Bronchial Hyperreactivity; Delayed-Action Preparations; Drug Therapy, Combination; Female; Fluticasone; Humans; Inflammation; Male; Middle Aged; Peak Expiratory Flow Rate; Quality of Life; Severity of Illness Index; Terbutaline; Time Factors; Treatment Outcome

2004

The use of patch formulation of tulobuterol, a long-acting beta2-adrenoreceptor agonist, in the treatment of severe pediatric asthma.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2006, Volume: 96, Issue:6

Topics: Administration, Cutaneous; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Asthma; Beclomethasone; Bronchodilator Agents; Child; Drug Therapy, Combination; Humans; Peak Expiratory Flow Rate; Terbutaline

2006